INTRODUCTION
============

Second or multiple primary lung cancer is defined as 2 or more pulmonary tumors developing independently of each other in location and/or time.^[@R1]^ Second primary lung cancers are divided into 2 subgroups, synchronous and metachronous lung cancer, according to its simultaneity.^[@R1]^ The incidence of second primary lung cancers is relatively low, showing approximately 16% of patients who were treated for initial lung cancer.^[@R2]^ In recent years, the incidence of second primary lung cancers seems to have increased as the result of longer survival after resection of primary cancers^[@R3]^ and the use of early detection tools such as multislice spiral computed tomography (CT) and positron emission tomography (PET). However, the development of second primary lung cancer with different histologic types is a very rare pathologic condition, especially occurrence of small cell lung cancer, following non-small cell lung cancer. Moreover, up to date, there are little reports on the subsequent occurrence of second primary lung cancer in a patient treated with surgical resection for the initial lung cancer, especially in tracheal region.

Herein, we introduce our interesting experience of subsequent occurrence of second primary lung cancer with different histologic types, at one time as squamous cell carcinoma and the other time as small cell lung carcinoma, limited to only trachea in a patient treated with surgical resection for the squamous cell carcinoma initially.

CASE REPORT
===========

A 62-year-old-man visited our hospital with presenting the blood tinged sputum, who was looked relatively well except inspiratory wheezing on bilateral lung field through physical examination. On his past history, 3 years ago, he was diagnosed as non-small cell lung cancer, squamous cell carcinoma of anatomical stage IIB (T2N1M0) by TNM system (Figure [1](#F1){ref-type="fig"}) presenting as a mass with high-uptake of 18-fluorodeoxyglucose (FDG) on PET/CT scan (Figure [2](#F2){ref-type="fig"}A and C). Thus, he was treated with surgical resection of left pneumonectomy and adjuvant chemotherapy in which regimen was composed of paclitaxel and carboplatin. At the time of the diagnosis, he was a current smoker with 30 pack-year history. After the completion of chemotherapy, for 17 months, there was no evidence of recurrence of lung malignancy on his health surveillance. However, at 18 months after the treatment, follow-up PET/CT scan (Figure [2](#F2){ref-type="fig"}B and D) and spiral chest CT scan (Figure [3](#F3){ref-type="fig"}A) revealed an isolated mass on the left lateral side of anterior tracheal wall. To evaluate the tracheal mass further, he was underwent bronchoscopy with endotracheal biopsy (Figure [3](#F3){ref-type="fig"}B), and the histologic type of the mass was confirmed as squamous cell carcinoma with showing typical pathologic features in which tumor cells are arranged in a solid sheet-like pattern and reveal vesicular nuclei with prominent nucleolus, eosinophilic plump cytoplasm, numerous mitoses, and intercellular bridges (Figure [3](#F3){ref-type="fig"}C). The recurred tracheal mass was treated with stump resection and bronchoplasty, accompanying adjuvant chemotherapy using previous regimen. Until he visited hospital due to blood-tinged sputum, he had shown no sign and symptoms of recurred malignancy for about 10 months.

![Chest radiograph (A) and CT scans (B, coronal view; C, lung setting view; D, mediastinal setting view) of the lung malignancy diagnosed initially 3 years ago. The radiologic images revealed an atelectasis of the left lung with pneumonic consolidation due to the heterogeneously enhanced lung mass on the left main bronchus. CT, computed tomography.](medi-94-e770-g001){#F1}

![PET/CT scans showed the mass with increased 18-FDG uptake in left main bronchus (arrow) at the initial diagnosis of lung malignancy (A, coronal view; C, transverse view). At first occurrence of second primary lung cancer in trachea, the small mass (arrow) was observed and its 18-FDG uptake was significantly high (B, coronal view; D, transverse view). 18-FDG, 18-fluorodeoxyglucose, PET, positron emission tomography, PET/CT, positron emission tomography/computed tomography.](medi-94-e770-g002){#F2}

![(A--C) The second primary lung cancer occurred in trachea firstly. CT scan (A) and bronchoscopic examination (B) revealed that the polypoid mass was located on the left anterolateral wall of trachea. (C) Representative H&E stained section. The tumor cells are arranged in a solid sheet-like pattern and reveal vesicular nuclei with prominent nucleolus, eosinophilic plump cytoplasm, numerous mitoses, and intercellular bridges (400×). (D--F) The second primary lung cancer occurred in trachea repetitively. CT scan (D) and bronchoscopic examination (E) revealed that the tracheal mass with very similar gross morphology to previous one was located on the right anterolateral wall of trachea. (F) Representative H&E stained section. Histologically, tumor cells showed round to oval nuclei with scant cytoplasm, finely granular chromatin pattern, and absent nucleoli (200×). (G--I) Follow-up chest CT scan (G), bronchoscopic finding (H), and PET/CT scan image (I). CT, computed tomography; H&E, hematoxylin and eosin. PET/CT, positron emission tomography/computed tomography.](medi-94-e770-g003){#F3}

For evaluation of his blood-tinged sputum, we performed chest roentgenogram, spiral chest CT, and bronchoscopy. Chest roentgenogram did not provide any of specific information related to hemoptysis or pulmonary hemorrhage. Spiral chest CT revealed slightly elevated mucosa in trachea at the level of between 4th and 5th thoracic spine without pulmonary hemorrhage or pneumonic infiltration (Figure [3](#F3){ref-type="fig"}D). Diagnostic bronchoscopy revealed a sessile type of polypoid mass on the right lateral side of anterior wall in trachea, which was approximately 3 to 4 cm apart from carina (Figure [3](#F3){ref-type="fig"}E). Unexpectedly, histologic examination of endotracheal mass established small cell lung cancer, in which tumor cells showed round to oval nuclei with scant cytoplasm, finely granular chromatin pattern, and absent nucleoli (Figure [3](#F3){ref-type="fig"}F). Moreover, the tumor cells also showed positivity for the neuroendocrine markers including CD56, chromogranin, and synaptophysin as well as thyroid transcription factor-1 (TTF-1). This newly developed tracheal mass in the patient was isolated without local invasion and distant metastasis, thus, it was diagnosed as second primary lung cancer, small cell lung carcinoma of limited stage and treated with concurrent chemoradiotherapy; 9 cycles of irinotecan and carboplatin plus definitive radiotherapy. We assured disappearance of endotracheal recurrence without any involvement of other tissues through spiral chest CT, diagnostic bronchoscopy, and PET-CT and then ceased the concurrent chemoradiotherapy. Up to 5-year follow-up, he has shown neither recurrence nor other events involved, and he has maintained the complete remission state (Figure [3](#F3){ref-type="fig"}G--I).

DISCUSSION
==========

Lung cancer is the leading cause of cancer death in both males and females worldwide, although the incidence of lung cancer decreased in some developed countries.^[@R4]^ However, the incidence of second primary lung cancers have increased in recent years thank to the introduction of various diagnostic modalities and the development of new therapeutic agents and techniques. Especially, despite the expectation of long-term survival after curable resection in the case of stage I non-small cell lung cancer, the recurrence or new cancers can be emerged in a third of the patients.^[@R5]^ Therefore, the longer the patients survive from initially presented as early stage of lung cancer, the higher risk for second cancers increases.

The majority of second primary lung cancers have similarity with initially presented lung cancers in histologic type, and the reason proposed is the common genetic background between first primary lung cancers and second primary lung cancers.^[@R6]^ However, a few cases have been reported on the different histologic types of second primary lung cancers from the primary cancers. It means that second primary lung cancers with different histologic types can be sporadically developed by cancer cell transformation, that is, this issue remains to be clarified. Recently, Rice and colleagues investigated the risk of second primary lung cancers in patients treated with surgical resection for stage I non-small cell lung cancer and revealed that the risk of second primary lung cancers in them is 1.99 per 100 patient-years.^[@R7]^ In addition, the histologic type of second primary lung cancers is correlated with the first primary lung cancer. The frequently involved sites are both upper lobes. However, the repetitive occurrence of second primary lung cancers has rarely been reported.

In our current case, the patient experienced the repetitive occurrences of second primary lung cancer, in which each second primary lung cancer showed different histologic type, moreover, their locations wandered, possessing similar gross morphology within trachea. Given each histologic type (ie, non-small cell lung cancer versus small cell lung cancer), they should be treated with different therapeutic agents and methods. Moreover, they have very different prognosis, it gives clinicians a lesson that the efforts for identification of the newly developed cancerous lesions histologically are important, even though the lesions look similar each other grossly.

As for pathologic features of both tumors, the characteristics of squamous cell carcinoma include intercellular bridges, individual cell keratinization, and squamous pearl formation.^[@R8]^ According to the WHO classification, squamous cell carcinoma can be divided into papillary, clear cell, small cell and basaloid subtypes,^[@R9]^ however, the clinical and prognostic utility is relatively weak. In contrast to non-small cell lung cancer, small cell lung cancer shows the morphologic characteristics as follows; tumor cells are usually smaller than lymphocytes, nucleoli is absent or faint, nuclear chromatin is finely granular or uniform, nuclear-to-cytoplasmic ratio is higher than non-small cell lung cancer, nuclear molding is frequent, necrosis is common and often extensive, cell shape is usually fusiform, and basophilic staining of vessels and stroma are detected occasionally.^[@R10]^ Despite that the most important stain is a high-quality hematoxylin and eosin (H&E) stain for the pathologic diagnosis of small cell lung cancer, immunohistochemistry, specifically for neuroendocrine markers, is very useful. The most useful neuroendocrine markers include CD56, chromogranin, and synaptophysin.^[@R11],[@R12]^ TTF-1 expression is present in 70% to 90% of small cell lung cancer, however, it is known that TTF-1 can be positive in 44% to 90% of extrapulmonary small cell carcinoma, indicating that TTF-1 is not useful for defining the primary site of small cell carcinoma.^[@R9],[@R10],[@R13],[@R14]^ The differentiation of small cell lung cancer from non-small cell lung cancer including squamous cell carcinoma is usually performed based on multiple features of high-quality H&E stained pathologic specimens such as cell size, nuclear-to-cytoplasmic ratio, nuclear chromatin, nucleoli, nuclear molding, cell shape, and hematoxylin vascular staining as described above.^[@R15],[@R16]^ Distinct immunohistochemical features of small cell lung cancer include the expression of neuroendocrine markers and/or TTF-1 in tumor cells of lung.^[@R11]^

Metachronously occurred tumors are detected in relatively early stage to be cured through complete resection. Several surgical series describe 5-year survival rates are ranging from 11% to 52% after operation of metachronous tumor.^[@R17]^ The patient in this current case underwent the surgical resection for the second primary lung cancer occurred previously, and the second primary lung cancer developed at second time was treated with concurrent chemoradiotherapy according to the standard therapeutic approach for small cell lung cancer.

In summary, we describe a unique and intriguing case of repetitive second primary lung cancer occurred in trachea. They occurred at very close sites with similar gross morphology, however, unexpectedly their histologic types were different each other; non-small cell lung cancer versus small cell lung cancer. Although many physicians will encounter this pathologic situation very scarcely, if any, they should actively attempt to identify the histologic characteristics of second primary lung cancers for the correct and adequate treatment. In addition, the pathophysiology and clinical characteristics including genetic background of the second primary lung cancers with different histologic types should be investigated in the future.
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